NDAINJECTIONINJECTABLE, LIPID COMPLEXPriority Review
Approved
Nov 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
ABELCET (amphotericin b) by Leadiant Biosciences is mechanism of action amphotericin b, the active ingredient of amphotericin b liposome for injection, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. First approved in 1995.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABELCET is a liposomal formulation of amphotericin B, a polyene antifungal antibiotic approved in 1995 for treating invasive fungal infections. It works by binding to ergosterol in the fungal cell membrane, disrupting cell permeability and causing fungal cell death. The liposomal delivery improves penetration into fungal cells while reducing mammalian cytotoxicity compared to conventional amphotericin B.
LOE Approaching
Product is approaching loss of exclusivity, signaling potential team downsizing and shift toward lifecycle management and cost containment strategies.
Mechanism of Action
Mechanism of Action Amphotericin B, the active ingredient of amphotericin B liposome for injection, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. It forms transmembrane channels leading to alterations in cell permeability through which monovalent…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
Started Oct 2026
18 enrolled
Chronic Pulmonary Aspergillosis
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Started Sep 2026
428 enrolled
Talaromycosis
Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients
Started Jul 2026
120 enrolled
Invasive Fungal InfectionSolid Organ TransplantationOpportunistic Infections
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Started Feb 2026
60 enrolled
Invasive Mould Infection
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
Started Sep 2025
38 enrolled
Fungal Disease
Worked on ABELCET at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.